Award Sub-Category: Medical & Biotech

Moderna’s BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster
(mRNA-1273.22) targets the original strain of SARS-CoV-2 and BA.4/BA.5
Omicron subvariants. It was developed per U.S. FDA guidance to protect
against COVID-19 variants for fall and winter 2022. mRNA-1273.222 is
authorized in the U.S., UK, EU and other countries.

This innovation uses coordinated supramolecular complex (CSC) technology
to develop an eye drop formulation for treating wet age-related macular
degeneration (AMD). CSC for posterior eye delivery addresses the
shortcomings of current treatments, providing a non-invasive and
self-administrable alternative for patients.